The Center for Molecular Innovation and Drug Discovery (CMIDD) has received a three-year, $1 million grant from the National Cancer Institute (NCI) to discover effective therapeutic treatment against metastatic prostate cancer.
More than 80% of cancer-related deaths stem from the formation of metastases, incurable secondary tumor growths that spread from their original cancer sites. However, effective anti-metastatic treatments are virtually non-existent due to a lack of potent and selective molecules to target metastasis regulators.
Under the direction of Dr. Karl Scheidt, PI, Director of CMIDD and Professor of Chemistry and Pharmacology, CMIDD researchers will collaborate with the OHSU Knight Cancer Institute to study the MAP2K4 protein, which they identified as a critical mediator of metastasis in prostate cancer.
“This project now gives us an unprecedented opportunity to develop new therapy designed to inhibit human prostate cancer cell movement in humans,” says Dr. Raymond Bergan, Associate Director of the Knight Cancer Institute and lead project collaborator with the Center.
This NCI grant will support high throughput screening, medicinal and synthetic chemistry, and biological analysis research to develop first generation anti-metastatic agents for prostate cancer treatment.